Overview

A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy Adults

Status:
COMPLETED
Trial end date:
2025-02-25
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess the effect of a therapeutic and supratherapeutic dose of zelicapavir on the corrected cardiac QT interval relative to a placebo and positive control in healthy participants.
Phase:
PHASE1
Details
Lead Sponsor:
Enanta Pharmaceuticals, Inc
Treatments:
EDP-938
Moxifloxacin